Early C-reactive protein reduction predicts survival in real-world extensive-stage small cell lung cancer treated with first-line adebrelimab-based immunotherapy

Early reduction in CRP levels during adebrelimab-based chemoimmunotherapy is an potentially predictor of improved survival in ES-SCLC, despite dissociation from initial radiologic response. This suggests that CRP kinetics could serve as a practical, real-world biomarker for prognostication and early efficacy assessment in ES-SCLC. Prospective validation in larger cohorts is essential to confirm these findings.